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ABSTRACT
The pharmacokinetic-pharmacodynamic (pk-pd) characteriza-
tion of the in vivo antinociceptive interaction between (1)-O-
desmethyltramadol [(1)-M1] and (2)-O-desmethyltramadol
[(2)-M1], main metabolites of tramadol, was studied in three
groups of rats. (1)-M1 and (2)-M1, both with different pd
properties, were studied under steady-state and nonsteady-
state conditions, depending on the group. Plasma drug con-
centration and antinociception were simultaneously measured
in each animal by using an enantioselective analytical assay
and the tail-flick test, respectively. Respiratory depression also
was evaluated in another series of experiments according to
the same experimental conditions. The pk behavior was similar
for both enantiomers and no significant (P . .05) interaction
between two compounds was found at this level. However, a
significant (P , .01) potentiation in the antinociceptive effect
elicited by (1)-M1 was found during and after (2)-M1 admin-
istration. The pd model used to describe the time course of the
antinociception in the presence of (1)-M1, (2)-M1, or both is
based on previous knowledge of the compounds and includes
the following: 1) an effect compartment model to account for
the opioid effect of (1)-M1, and 2) an indirect response model
accounting for the release of noradrenaline (NA) caused by
(1)-M1, and the inhibition of the NA reuptake due to the action
of (2)-M1. The model predicts a positive contribution to antino-
ciception of the predicted increasing levels of NA. No signifi-
cant (P . .05) respiratory effects were seen during or after
(1)-M1 and (2)-M1 administration.
Tramadol is a safe and effective analgesic used in the
management of pain and has recently been included in the
group of m-receptor partial agonists, which includes meptazi-
nol (Bowdle, 1998). Results carried out in rats showed that
its potency is comparable to that of codeine or dextropropo-
xiphene (Hennies et al., 1988). However, experimental data
suggest that tramadol exerts part of its analgesic effect
through the activation of the central inhibitory monoamin-
ergic pathway because its effect has been partially blocked by
a2-adrenoceptor antagonists such as yohimbine (Raffa et al.,
1992; Sevcik et al., 1993). The ability of tramadol to inhibit
the neuronal uptake of monoamines in the same concentra-
tion range at which it binds to m-opioid receptors, which is
very different for morphine or codeine, makes tramadol an
“atypical” opioid (Raffa and Friderichs, 1996). The coexist-
ence of opioid and nonopioid mechanisms has been shown in
several in vitro and in vivo studies (Hennies et al., 1988;
Driessen et al., 1993; Sevcik et al., 1993; Frink et al., 1996;
Raffa and Friderichs, 1996; Bamigbade et al., 1997).
Tramadol is a racemic (1:1) mixture of two enantiomers,
(1)-tramadol and (2)-tramadol, which are essentially metab-
olized by the liver (Lee et al., 1993) forming mainly (1)-O-
desmethyltramadol [(1)-M1] and (2)-O-desmethyltramadol
[(2)-M1] metabolites, respectively. In vitro studies have
shown that the (1)-enantiomers had greater affinity for the
opioid receptor system than the (2)-enantiomers, with
(1)-M1 being the compound with the highest affinity for
m-receptors (Frink et al., 1996; Lai et al., 1996). However, the
capacity to inhibit the synaptosomal uptake of norepineph-
rine is mainly due to its (2)-enantiomers (Raffa et al., 1992;
Driessen et al., 1993; Frink et al., 1996).
In vivo studies have demonstrated an analgesic action of
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tramadol in different animal models. This effect was not
completely abolished by the administration of naloxone, an
opiate antagonist, as occurs with morphine (Hennies et al.,
1988; Kayser et al., 1992; Raffa et al., 1993; Bian et al., 1996;
Desmeules et al., 1996). These results support the coexist-
ence of dual analgesic mechanisms due to the interaction
between the enantiomers of tramadol (Raffa et al., 1995). The
action of the opioid system is potentiated by the reinforce-
ment of noradrenergic neurotransmission, especially on spi-
nal neurons (Fairbanks and Wilcox, 1999).
Although these types of interactions have been identified
and described in several in vivo studies (Raffa et al., 1993),
most of these focus on dose-response relationships. To our
knowledge there has so far been no attempt to propose a
pharmacokinetic-pharmacodynamic (pk-pd) model capable of
describing and predicting the in vivo time course of antino-
ciception when an agonist-opioid and a noradrenaline (NA)
uptake blocker are concomitantly administered. Therefore,
the aim of the present study was to investigate the in vivo
interaction between the enantiomers of M1 in the antinoci-
ceptive response by using a mechanism-based pk-pd model.
We have recently shown in our laboratory that the in vivo
antinociceptive response elicited by (1)-M1 in the tail-flick
test could be adequately described by an appropriate pk-pd
model (Valle et al., 2000).
Materials and Methods
Animals and Surgery
Male Sprague-Dawley rats with a body weight between 210 and
245 g were used in the experiments. These animals were kept on a
controlled light/dark cycle (8:00 AM to 8:00 PM), with a constant
temperature of 20°C and humidity of 70°C for a week before exper-
iments were performed. Food (Standard Laboratory Rat, Mouse, and
Hamster diets; Panlab, Barcelona, Spain) and water were available
ad libitum.
One day before the experiments, the animals were housed indi-
vidually in plastic cages and three permanent cannulas were im-
planted under light ether anesthesia: one in the left femoral artery
(0.3 mm i.d., 20 cm long; Vygon, Ecouen, France), used for blood
sample collection, and two in the right jugular vein (0.5 mm i.d., 10
cm long; Vygon) for (1)-M1 and (2)-M1 administration. All cannulas
were filled with a physiological saline solution containing heparin
(20 I.U./ml) to prevent clotting. The cannulas were tunneled under
the skin and externalized on the dorsal surface of the neck. The
protocol of the study was approved by the Committee on Animal
Experimentation of the University of the Basque Country.
Pk-Pd Experiments
Three groups of five or six animals each were randomly assigned
to different drug treatments. The experiments were always started
between 8:30 and 9:00 AM. Each group received (1)-M1 and (2)-M1
according to the protocol summarized in Fig. 1.
Experiment I. (1)-M1 was administered to the animals from
group I according to a Wagner infusion scheme calculated to reach
rapidly a steady-state plasma concentration of 200 ng ml21 (Wagner,
1974). The animals received an i.v. bolus of 0.73 mg kg21 and imme-
diately afterward, a 160-min continuous i.v. infusion at a rate of
0.023 mg kg21 min21. Animals received 10-min i.v. infusion of
(2)-M1 at a rate of 0.2 mg kg21 min21 starting 120 min after the
beginning of the experiment.
Experiment II. Group II received a 10-min i.v. infusion of (1)-M1
at a rate of 0.2 mg kg21 min21 and another 10-min i.v. infusion of
(2)-M1 starting 40 min after the beginning of the experiment at a
rate of 0.2 mg kg21min21.
Experiment III. The animals from group III received two i.v.
infusions according to the Wagner infusion scheme for both com-
pounds, to reach rapidly a steady-state plasma concentration of 200
ng ml21 for (1)-M1 and 500 ng ml21 for (2)-M1. The first compound
was administered as an i.v. bolus of 0.73 mg kg21, and immediately
afterward a 180-min continuous i.v. infusion was given at a rate of
0.023 mg kg21 min21. The second compound was administered at 90
min after the start of the experiment as an i.v. bolus of 2.55 mg kg21
followed by a 90-min continuous i.v. infusion at a rate of 0.068 mg
kg21 min21.
To determine the pk of (1)-M1 and (2)-M1, several blood samples
(125–225 ml) were collected at fixed intervals over the time course of
the experiments. Blood samples were centrifuged at 2500 rpm for 15
min and the plasma was stored at 220°C until HPLC analysis (see
below).
The antinociception for the three above-mentioned groups was
simultaneously evaluated at the same time as blood samples were
collected. This effect was measured by the radiant-heat tail-flick
technique to assess the nociception threshold (D’Amour and Smith,
1941). Tail-flick latency was measured automatically with a Letica
analgesimeter (Letica, Barcelona, Spain). The intensity of heat was
adjusted so that baseline latencies were between 2 or 3 s; animals
with higher baseline latencies were excluded from the study. A
maximum cutoff time of 10 s was used to prevent tissue damage.
Three extra (control) groups that received physiological saline solu-
tion at different rates according to the protocols previously described
were used to evaluate the effect of the length of infusion and re-
peated tail-flick measurements in the time course of antinociception.
Respiratory Depression
Experiment IV. Twelve animals were randomly divided into four
groups to study the possible interaction between (1)-M1 and (2)-M1
on the respiratory depression. These compounds were concomitantly
administered according to the same scheme of the infusions as de-
scribed above (Fig. 1). Additionally, an extra group (control group)
received a physiological saline solution for 180 min to evaluate the
effect of the length of the infusion on the pH, pCO2, and pO2 basal
levels. Several arterial blood samples (100 ml) were collected before,
during, and after infusions to measure the pH, pCO2, and pO2 levels
by a gas analyzer (AVL 990; AVL Biomedical Instruments, Graz,
Austria).
Drug Assay
The plasma concentrations of (1)-M1 and (2)-M1 were deter-
mined by a sensitive and stereoselective HPLC assay (Campanero et
al., 1999). Briefly, plasma samples (50–100 ml) were transferred into
glass tubes mixed with 50 ml of internal standard (ketamine HCl), 1
ml of Tris buffer (pH 9.5, 0.05 M), and 6 ml of tert-butyl methylether.
The mixture was shaken for 1 min and the organic layer was sepa-
rated after centrifugation at 3500 rpm for 10 min. The organic phase
was evaporated to dryness at 40°C under reduced pressure (rotatory
evaporator, model 4322000; Labconco, Kansas City, MO). The resi-
Fig. 1. Experimental design for (1)-M1 and (2)-M1 administration in
each of the three groups of the study. The length of different infusions is
represented by solid bars: u, (1)-M1; and f, (2)-M1.
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due was reconstituted in 250 ml of mobile phase and vortex mixed for
1 min. A 100-ml aliquot was then injected into the HPLC system.
The chromatography system consisted of a Hewlett Packard
HPLC (Waldbronn, Germany) equipped with an HP 1050 quaternary
pump, an HP 1050 autosampler, and an HP 1046A fluorescence
detector. The excitation and emission l were 199 and 301 nm, re-
spectively.
The analytical separation was performed at 20 6 3°C by a Chiral-
cel OD-R column (250 3 4.6 mm i.d.) packed with cellulose Tris
(3,5-dimethylphenylcarbamate) coated in silica (10 mm) (Daicel
Chemical Industries, Tokyo, Japan), preceded by a reversed phase,
100 3 4-mm end-capped column packed with 3 mm of C8 silica
reversed phase particles (Hypersil BDS C18; Hewlett Packard). A
guard column (4 3 4 mm) packed with Lichrosphere 100 DIOL (5
mm) from Merck (Barcelona, Spain) was connected to the column
system. The mobile phase consisting of acetonitrile plus 0.05 M
sodium dihydrogen phosphate, thiethylamine (0.09 M), and sodium
perchlorate (0.2 M), adjusted to pH 5.5 with hydrochloric acid 2 M (20
acetonitrile/80 buffer, pH 5.5), was filtered through a 0.45-mm pore
size membrane filter. The flow rate was 0.6 ml min21. The limit of
quantification of each enantiomer was 10 ng ml21 and the method
was linear from 10 to 1000 ng ml21. The intra- and interassay
coefficients of variation were 2.8 and 4.9%, respectively.
Data Analysis
All the analysis was performed by using the population approach
with NONMEM V (Beal and Sheiner, 1992). During the analysis the
pk model was built first and then, with all parameters of the pk
model fixed, the pd model was elaborated. The observations are
expressed as follows: OBSij 5 f(ui, D, tj) 1 eij, where OBSij refers to
the jth observation (plasma drug concentration, or antinociceptive
effect), obtained at time tj in the ith animal; f represents the struc-
tural model; ui represents the set of the parameters (pk or pd) for the
ith animal; D is the administered dose, and eij represents the resid-
ual shift of the observation from the model predictions. eij are ran-
dom variables assumed to be symmetrically distributed around zero
with variance denoted by s2. Although in the previous expression an
additive model was used to relate observations to predictions, differ-
ent error models were tested.
For each of the elements of ui, the following model was used: pi 5
ppop { exp(hi), where pi represents an arbitrary pk or pd parameter of
the ith animal; ppop is the mean population estimate, and hi, the shift
of the parameter of the ith animal from the population mean esti-
mate, are random variables assumed to be symmetrically distributed
around zero with variance-covariance matrix V with diagonal ele-
ments (v21,. . . ,v
2
m), m being the number of pk or pd parameters
estimated in the model.
Pk Models. The disposition of the drug in the body was charac-
terized by compartmental models. Distribution and elimination of
(2)-M1 were modeled as linear processes. However, as has been
described before for (1)-M1 (Valle et al., 2000), the plasma clearance
(Cl) was described as a function depending on the time after the start
of the infusion as follows: Cl 5 Cl1 z exp(2Cl2 z t); Cl1 and Cl2 are pk
parameters to be estimated by the model and t represents time after
the start of the infusion.
Pd Models. The pd model accounting for the in vivo interaction
between (1)-M1 and (2)-M1 on the antinociceptive effect is repre-
sented in Fig. 2. It consists of three submodels, which were based on
the following considerations.
Submodel 1. An effect compartment model (Sheiner et al., 1979)
has been shown to be adequate to account for the disequilibrium
between plasma and biophase concentrations of (1)-M1 (Valle et al.,
2000). In Fig. 2, ke0 is the first order rate constant governing the
distribution of (1)-M1 from plasma to biophase.
Submodel 2. The administration of opioid drugs results in a
concomitant release of NA, and there is evidence that such a release
may contribute to the antinociceptive effect of the opioid (Bouaziz et
al., 1996). In Fig. 2, KIN and KOUT represent the first order rate
constants of release and reuptake of NA, respectively.
In the absence of (2)-M1, the rate of change of NA is represented
by the following expression:
dNA
dt 5 KIN z C~1)-M1 2 KOUT z NA , (1)
where C(1)-M1 is the plasma concentrations of (1)-M1.
Submodel 3. (2)-M1 is able to inhibit the reuptake of NA (Raffa
et al., 1992; Driessen et al., 1993; Frink et al., 1996). In the presence
of (2)-M1 the rate of change of NA is described by the following
expression:
dNA
dt 5 KIN z C~1)-M1 2 KOUT z I~t! z NA , (2)
where I(t) 5 (1 2 SL2 z C(2)-M1); C(2)-M1 is the plasma concentration
of (2)-M1 and SL2 is the slope of the linear relationship between
KOUT and C(2)-M1.
The final interaction model has the following expression: Antino-
ciception 5 E0 1 SL z Ce(1)-M1 z (1 1 NA), where E0 represents the
baseline latency and SL the slope of the linear relationship between
the antinociceptive effect elicited by the opioid system and the effect
site (1)-M1 concentrations, Ce(1)-M1. The model predicts no effect of
the (2)-M1 enantiomer when it is administered alone, and assumes
that the plasma concentrations of (1)-M1 and (2)-M1 are the ones
directly related to the release and inhibition of the reuptake of NA,
respectively. Alternative models assuming 1) an effect compartment
for the effect of (2)-M1; 2) Ce(1)-M1 instead of C(1)-M1 is directly
related with NA release; or 3) effect versus concentrations can be
better described by an Emax or sigmoidal Emax models also were fitted
to the data. In addition, a model ignoring the contribution of (2)-M1
to the antinociceptive effect was explored.
Model selection was based on a number of criteria, such as the
exploratory analysis of the goodness of fit plots, the estimates and
the confidence intervals of the fixed and random parameters, and the
minimum value of the objective function provided by NONMEM; the
difference in the objective function between two hierarchical models
was compared with a chi-square distribution in which a difference of
approximately 4, 6, and 11 points was significant at the 5, 1, and
0.1% levels, respectively.
Statistical Analysis
The paired Student’s t test (two-tailed) was used for comparison
between the maximum effects after (1)-M1 administration and after
(2)-M1 administration. To evaluate the respiratory depression in all
Fig. 2. Schematic representation of the pd model selected during the
analysis of the in vivo interaction between (1)-M1 and (2)-M1 in the
antinociceptive effect.
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groups an ANOVA followed by the F test was used. A probability
level of P , .05 was considered to be statistically significant.
Compounds
The hydrochloride salts of (1)-M1 and (2)-M1 were kindly sup-
plied by Gru¨nenthal GmbH (Aachen, Germany). Ketamine HCl (in-
ternal standard) was purchased from Sigma Chemical Co. (Madrid,
Spain). All reagents and solvents were of analytical grade.
Results
Pk of (1)-M1 and (2)-M1. Figure 3 shows the mean
observed plasma concentrations versus time profiles for both
enantiomers over the time course of the experiment. The
infusion design produced a rapid steady state in plasma for
(1)-M1 in groups I and III, and for (2)-M1 in group III.
Figure 3 also represents the typical model predictions. The
selected model for both enantiomers was a two-compartment
model. For (1)-M1 total Cl was modeled as a function depen-
dent on the time after the start of the infusions. Estimates of
the fixed and random parameters for (1)-M1 are listed in
Table 1. Interanimal variability could be estimated in total
Cl and apparent volume of distribution of the peripheral
compartment (VT) resulting in 37 and 30%, respectively.
Estimates of the pk parameters for (2)-M1 are listed in
Table 2. Their values were very similar to that obtained for
(1)-M1, the main difference being the fact that Cl was con-
stant over time. Interanimal variability could be estimated in
total Cl, intercompartmental clearance (Cld), and in the ap-
parent volume of the VT. The variability in the total clear-
ance (15%) was low in comparison to the 50 and 30% esti-
mates obtained for Cld and VT, respectively. Residual
variability was less than 10% for both (1)-M1 and (2)-M1.
Different models testing the possible effect of the plasma
concentrations of (1)-M1 on the value of the pk parameters of
(2)-M1, and vice versa also were fitted, however, no improve-
ments were found in respect to the model showed in Fig. 3.
Pk-Pd Results. The mean observed antinociceptive effect
versus time profiles for the three groups are shown in Fig. 4.
The antinociceptive baseline values did not significantly (P .
.05) differ between groups. At the time of the start of (2)-M1
administration, the observed mean antinociceptive effect
elicited by (1)-M1 was 7.6 6 0.5, 8.3 6 0.7, and 5.1 6 0.3 s in
groups I, II, and III, respectively. These values were signifi-
cantly increased (P , .05) to values of 10 s for group I and
8.6 6 1.7 s for group III, at the times the infusion of (2)-M1
was stopped. However, the increase to 9.3 6 1.4 s in group II
was not statistically significant; but, it should be taken into
account that for group II, at times the infusion of (2)-M1 was
started, plasma concentrations of (1)-M1 were already de-
creasing. In groups I and III mean plasma (1)-M1 concen-
trations remained constant during the (2)-M1 infusion (Fig.
3). These results suggested an enhancement in the antinoci-
ception due to the presence of (2)-M1. Peak effect after
(2)-M1 administration was observed at 130, 50, and from 120
to 180 min for group I–III, respectively. No significant differ-
ences (P . .05) from the basal latency values throughout the
period of the experiment were found in each of the extra
control groups.
Figure 4 also shows the typical predictions for two of the
models tested: the simplest model (an effect compartment
model), not including drug interaction and assuming that all
the effect is caused by (1)-M1 action; and the final selected
model, including the inhibition of the NA reuptake by (2)-M1
action. This last model was capable of describing the effect of
(1)-M1 and also the increase in observed antinociception
immediately after (2)-M1 administration, in the three
TABLE 1
Pharmacokinetic parameter estimates of (1)-M1
Estimates of interanimal variability are expressed as coefficients of variation (%).
Precision of the estimates is expressed as relative standard error in parenthesis.
Relative standard error is standard error divided by the parameter estimate.
Parameter Estimate InteranimalVariability
Vc(l) 0.066 (0.57) N.E.
VT(l) 0.590 (0.06) 30 (0.66)
Cld (l min
21) 0.075 (0.11) N.E.
Cl1 (l min
21) 0.034 (0.08) 37 (0.54)
Cl2 (min
21) 0.002 (0.36)
Vc, initial volume of distribution; VT, apparent volume of distribution of the
peripheral compartment; Cld, intercompartmental clearance; Cl 5 Cl1 z e
2Cl2 z t; N.E.,
not estimated in the model.
Fig. 3. Pk profiles of (1)-M1 (F) and (2)-M1 (E) in group I (top), II
(middle), and III (bottom). The points represent the mean observed con-
centrations, the solid lines the typical model predictions, and the vertical
lines are the standard deviations. The solid bars represent the length of
different infusions: u, (1)-M1; and f, (2)-M1.
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groups of animals. Note, at times (2)-M1 infusion was
stopped, the 2-fold differences between the mean observed
effect and the prediction obtained from the model does not
include the (1)-M1-(2)-M1 interaction (Fig. 4, middle). Table
3 lists the estimate of the pd parameters for the final model.
Interanimal variability could be estimated in only two pa-
rameters, SL and ke0. In the range of concentrations seen in
the current study the pd relationships for (1)-M1 and (2)-M1
were found to be linear. Figure 5 represents the predicted
time profiles of arbitrary NA levels on the basis of the se-
lected model.
Respiratory Depression Results. Mean observed time
profiles for pH, pCO2, and pO2 are depicted in Fig. 6. (1)-M1
administration did not elicit significant changes in any of the
respiratory parameters (P . .05). In addition, despite the
increase seen in the antinociceptive effect, the administra-
tion of (2)-M1 had no significant implications for the respi-
ratory function (P . .05).
Discussion
In this study the in vivo interaction on the antinociceptive
effect between the two main metabolites of tramadol, (1)-M1
and (2)-M1, has been characterized by using a pk-pd model.
The interaction between opiate drugs and a2-adrenergic ago-
nists or monoamine reuptake inhibitors has been reported in
the literature by several studies. Meert and De Kock (1994)
found a potentiation in the effect elicited by opioids when
a2-adrenergic agonists were concomitantly administered.
The estimate of ED50 for fentanyl in the tail-withdrawal
response test when it was given 120 min after xylazine treat-
ment decreased from 0.22 to 0.056 mg kg21 when xylazine
doses were increased from 0.63 to 40 mg kg21, respectively.
Similar results were found in the duration of sufentanil an-
algesia after medetomidine i.v. administration. A 0.063 mg
kg21 dose of medetomidine provided a statistical (P , .05)
increase in the duration of analgesia after an i.v. adminis-
tration of a 1.25-mg dose of sufentanil. Taiwo et al. (1985) also
reported a potentiation of morphine antinociception mea-
sured by tail-flick test after tricyclic antidepressant admin-
istration. An s.c. dose of 0.5 mg kg21 morphine did not
produce any change in the antinociceptive baseline, but when
the same s.c. dose was given together with 30 mg of amitrip-
tyline intrathecally, all animals reached maximum response.
There are still questions regarding the time course of the in
vivo effect of tramadol such as what is the role of the metab-
olites, or which kind of interaction occurs between (1)- and
(2)-enantiomers. Poulsen et al. (1996) suggested that forma-
TABLE 2
Pharmacokinetic parameter estimates of (2)-M1
Estimates of interanimal variability are expressed as coefficients of variation (%).
Precision of the estimates is expressed as relative standard error in parenthesis.
Relative standard error is standard error divided by the parameter estimate.
Parameter Estimate InteranimalVariability
Vc (l) 0.170 (0.08) N.E.
VT (l) 0.563 (0.12) 39 (0.45)
Cld (l min
21) 0.034 (0.14) 50 (0.46)
Cl (l min21) 0.031 (0.07) 15 (0.36)
Vc, initial volume of distribution; VT, apparent volume of distribution of the
peripheral compartment; Cld, intercompartmental clearance; N.E., not estimated in
the model.
Fig. 4. Time course of antinociception in group I (top), II (middle), and III
(bottom). Points represent the mean observed antinociception; dashed
lines represent typical predictions from the model, not including interac-
tion between the two enantiomers; and solid lines are the typical predic-
tions from the model described in Fig. 2 (selected model). Horizontal bars
represent the time and length of (1)-M1 (u) and (2)-M1 (f) infusions.
Vertical lines are the standard deviations.
TABLE 3
Results from the final population pharmacodynamic model selected
Estimates of interanimal variability are expressed as coefficients of variation (%).
Precision of the estimates is expressed as relative standard error in parenthesis.
Relative standard error is standard error divided by the parameter estimate.
Parameter Estimate InteranimalVariability
E0 (s) 2.98 (0.04) N.E.
SL (s ml ng21) 0.0216 (0.11) 19.7 (0.40)
ke0 (min
21) 0.041 (0.20) 47.9 (1.14)
SL2 (ml s
21 ng21) 0.00211 (0.04) N.E.
KIN (min
21) 0.60E-4 (0.38) N.E.
KOUT (min
21) 0.114 (0.13) N.E.
E0, antinociceptive baseline; SL, slope of the linear relationship between the
antinociceptive effect elicited by the opioid system and Ce(1)-M1; ke0, first order rate
constant of equilibrium between plasma and effect compartment; SL2, slope of the
linear relationship between KOUT and C(2)-M1; KIN, first order rate constant of
release of NA; KOUT, first order rate constant of NA reuptake; N.E., not estimated in
the model.
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tion of (1)-M1 is important for the effect of tramadol. On the
basis of these considerations and to make simpler the study
of all possible combinations between (1)-tramadol, (1)-M1,
(2)-tramadol, and (2)-M1, we focused our study only on the
combination of (1)-M1 and (2)-M1. An interaction is “a pri-
ori” expected given the opioid and monoamine reuptake in-
hibition properties of (1)-M1 and (2)-M1, respectively.
Previous studies carried out in our laboratory showed that
the in vivo antinociceptive effect of (1)-M1 in rats could be
adequately characterized by a pk-pd model (Valle et al.,
2000). We also found that high doses of (2)-M1 such as 8 mg
kg21 or steady-state plasma concentration levels of 700 ng
ml21 did not elicit antinociceptive response. To achieve the
goal of this study, results from that pk-pd study were used.
Steady-state plasma concentration levels of 200 ng ml21 of
(1)-M1 were found to exhibit an antinociceptive response
between 50 and 70% of the maximum response expressed as
percentage of the baseline. Choosing this target effect level
gave enough response window to evaluate the eventual po-
tentiation caused by the (2)-M1 administration and also
represented a significant response level with respect to the
baseline. The experimental design used in the current study
simultaneously explored the in vivo antinociception in three
different situations: 1) steady state for (1)-M1 and acute
administration of (2)-M1 (group I), 2) acute administration
for both compounds (group II), and 3) steady state for both
compounds (group III). This design has been determined to
be adequate to characterize the in vivo effect in cases where
there is delay in the distribution from plasma to biophase,
and development of tolerance occurs (Ekblom et al., 1993). In
fact, both phenomena were seen in our previous study with
(1)-M1 (Valle et al., 2000). The doses given for (2)-M1 were
chosen on the basis of the previous pk knowledge. We decided
to give first the infusion of (1)-M1 and then infuse the
(2)-M1 because this design allowed us to compare the even-
tual enhancement in antinociception caused by (2)-M1
within each animal in the study, and generate data suitable
to develop a pk-pd model describing drug interactions.
Figure 3 shows that the selected dosage regimen produced
the target-desired mean-observed concentrations rapidly in
groups I and III. In group II this value of concentration was
achieved at the time of (2)-M1 administration. The estimates
of pk parameters were very similar to those obtained previ-
ously when both compounds were administered alone (Valle
et al., 2000). These results show that there is no pk interac-
tion between the two enantiomers of the metabolite.
During the pd analysis in a first step, the observed effect
between the start of the experiment and before (2)-M1 ad-
ministration was related to the predicted (1)-M1 plasma
concentration. These analyses showed that there was a sig-
nificant delay for the drug in plasma to reach the biophase.
The estimate of ke0 was 0.04 min
21 and the slope of the effect
versus effect site concentration was estimated at 0.0208 s
min21. These values were very close to those previously
reported for (1)-M1 by using completely different dosage
designs for this compound. In fact, the target response (50–
70% of the maximum response) was achieved by using the
results from a previous study (Valle et al., 2000). When the
entirely observed effect versus time profiles were related to
the plasma concentrations of (1)-M1, the best fit result gave
the predictions represented by dashed lines in Fig. 4. It is
Fig. 5. Predicted arbitrary levels of NA versus time obtained from the
selected pd model depicted in Fig. 2 in group I (E), II (F), and III ().
Fig. 6. Mean observed levels of pH (upper panel), pO2 (middle panel), and
pCO2 (lower panel) in groups receiving (1)-M1 and (2)-M1 in a similar
infusion design that has been described in Fig. 1 for group I (E), group II
(F), and group III (U). Horizontal bars represent the time and length of
(2)-M1 infusions for group I (h), group II ( n ), and group III (u). Vertical
lines are the standard deviations.
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clear that this model is unable to describe the response
during and after (2)-M1 administration, especially the peak
effects. With this model, maximum differences between the
observed and model predicted effect were 2.1 s for group I, 4 s
for group II, and 2.4 s for group III. From these results it is
clear that a pd interaction between (1)-M1 and (2)-M1 has
occurred.
More pk-pd modeling is incorporating models accounting
for complex mechanisms of action (Gries et al., 1998; Brynne
et al., 1999; Gozzi et al., 1999). The model used in the current
study to describe the data represents a noncompetitive inter-
action model that is based on the following proposal mecha-
nism: systemic administration of therapeutic doses of opioids
elicits an increase of NA levels in the lumbar cerebrospinal
fluid; this spinal-released NA could contribute to analgesia
by an indirect stimulation of a2-adrenoceptors (Bouaziz et al.,
1996; Xu et al., 1997; Song et al., 1998). Therefore, the pres-
ence of the NA reuptake inhibitor (2)-M1 (Frink et al., 1996)
produces an augmentation of synaptic NA in spinal cord,
which is responsible for the enhancement in the antinocep-
tion elicited by (1)-M1.
This mechanism of action was modeled by using an indirect
response model, in which NA levels were released by (1)-M1
and (2)-M1 was acting to inhibit the first order rate constant
of elimination of NA levels from the spinal site. Figure 5
shows the arbitrary NA levels simulated as a function of
release promoted by (1)-M1 and inhibition of its reuptake
caused by (2)-M1. Studies with microdialysis techniques of-
fer the possibility to compare the observed time course of NA
and (1)-M1 and (2)-M1 concentrations in the spinal space
with the relative model-predicted concentrations of NA and
model-predicted drug concentrations obtained in the current
study.
The selected model represented by the solid line in Fig. 4,
which was able to adequately describe the entire course of
the drug effect, predicts no effect when there is no NA release
caused by opioid drug, which is compatible with the findings
that (2)-M1 has no antinociceptive effect per se. The esti-
mate of KOUT is much higher that that obtained for KIN,
suggesting that the contribution of NA to opioid antinocicep-
tion diminished quickly after release.
Tramadol given at doses higher than 1 mg kg21 i.v. pro-
duced respiratory depression in anaesthetized rats (Raffa
and Friederichs, 1996). That effect was abolished by previous
treatment with an enzyme inhibitor (SKF-525-A), suggesting
that the adverse effect was mainly due to the (1)-M1 pres-
ence. In previous studies we have seen that doses of (1)-M1
up to 2.5 mg kg21 i.v. did not produce any respiratory effect.
In the current study no respiratory depression was found
after (1)-M1 or (2)-M1 administration. These results show
that (2)-M1 in the range of plasma concentrations obtained
for (1)-M1 and (2)-M1 had no influence on the respiratory
parameters.
To summarize the results from the current study a pd
interaction reflected as a potentiation in the antinociceptive
effect was found between two enantiomers of the main active
metabolite of tramadol, O-desmethyltramadol. This phenom-
enon has successfully been modeled by using a noncompeti-
tive interaction model based on previous knowledge about
the mechanism of action of both compounds.
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